ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders. The Company is developing a portfolio consisting of its four product candidates, including pimavanserin, which is in Phase III development for the treatment of Parkinson’s disease psychosis. In addition, the Company has a product candidate in Phase II for chronic pain and a product candidate in Phase I for glaucoma, both in collaboration with Allergan, Inc., and ACP-106 in IND-track development. The Company’s product candidates include Pimavanserin, AGN-XX/YY, AC-262271 and ACP-106. The Company maintains two wholly owned subsidiaries: ACADIA Pharmaceuticals AB based in Malmo, Sweden and ACADIA Pharmaceuticals A/S based in Denmark.

Contact Details

Office Address

ACADIA Pharmaceuticals Inc.
3911 Sorrento Valley Blvd.
San Diego, CA, USA 92121
Phone: (858) 558-2871
Fax: (858) 558-2872


Chief Exec. Officer

Dr. Uli Hacksell Ph.D.

Chief Financial Officer

Mr. Thomas H. Aasen

Business Reviews for ACADIA Pharmaceuticals Inc.

Related Companies